Compare Gigacloud Technology Inc (GCT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Smith & Nephew plc — how do they compare? Gigacloud Technology Inc trades at $51.56 (market cap $1.84B), while Smith & Nephew plc trades at $29.6 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 6.8× Gigacloud Technology Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| GCT | SNN | |
|---|---|---|
Market Cap | $1.84B | $12.54B |
Sector | Technology | Health |
52-Week High | $53.25 | $38.70 |
52-Week Low | $25.44 | $28.73 |
Enterprise Value | $1.97B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
